Skip to content

SENSIMED Triggerfish

Randomized Clinical Investigation to Assess the Efficacy of SENSIMED Triggerfish Continuous IOP Monitoring

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01319604
Enrollment
59
Registered
2011-03-21
Start date
2011-03-31
Completion date
2012-05-31
Last updated
2012-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Brief summary

The purpose of the investigation is to investigate the relationship between the study device output and tonometric assessments.

Detailed description

60 subjects will be enrolled in total. Enrolled patients will be randomized into one of 8 device groups of 6 subjects each or into the control group containing 12 subjects. Patients in the device arm will receive one session of 3-to 24-hour continuous IOP monitoring with SENSIMED Triggerfish®. SENSIMED Triggerfish® monitoring will begin at 18h ± 2 hours for all patients. SENSIMED Triggerfish® will be installed randomly on right or left eyes. During SENSIMED Triggerfish® monitoring on one eye, GAT and/or Perkins IOP measurements will be taken in the fellow eye every 3 hours. Outside this time they will receive GAT and/or IOP measurements every 3 hours in both eyes until the end of the 24-hours period. Patients in the control group will receive GAT and/or ICare PRO IOP measurements every 3 hours for 24 hours in both eyes.

Interventions

Soft contact lens-based device for the continuous monitoring of IOP fluctuations

DEVICETonometer

Tonometric assessment of IOP

Sponsors

Sensimed AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Signed informed consent for the investigation * Confirmed diagnosis of primary open angle glaucoma or normal tension glaucoma of similar degree in both eyes * Age 18-85 * Stable anti-glaucomatous therapy 4 weeks before and throughout the investigation

Exclusion criteria

* Patients not able to understand the character and individual consequences of the investigation * Patients with contraindications for silicone contact lens wear * Wear of full frame metallic glasses during SENSIMED Triggerfish® monitoring * Diagnosis of pseudoexfoliation syndrome / pseudoexfoliative glaucoma and of pigment dispersion syndrome / pigmentary glaucoma * Severe dry eye * Patients who have had ocular surgery within the last 3 months * Corneal or conjunctival abnormality or irregularity hindering correct contact lens adaptation * Allergy to corneal anaesthesia * Simultaneous participation in other clinical research

Design outcomes

Primary

MeasureTime frame
Relationship between study device signal and tonometer readingduring 24 hours of study device wear

Countries

Belgium, Denmark, Spain, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026